[SCHEDULE 13G/A] Collegium Pharmaceutical, Inc. SEC Filing

Rhea-AI Filing Summary

Renaissance Technologies LLC and Renaissance Technologies Holdings Corporation report beneficial ownership of 1,521,170 shares of Collegium Pharmaceutical common stock, representing 4.82% of the class. The filers state they have sole voting and sole dispositive power over these shares and no shared voting or dispositive power. The filing affirms the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control. It also notes that certain funds managed by Renaissance have rights to receive dividends and sale proceeds related to these shares. The report identifies one filer as an investment adviser and the other as a holding company.

Insights

Financial Analyst

Renaissance holds a non-controlling 4.82% stake with sole control over voting and disposition.

The disclosure shows a meaningful but sub-5% position: 1,521,170 shares (4.82%). Sole voting and dispositive power indicates Renaissance can vote these shares and decide sales without shared authority, which matters for proxy votes or corporate actions. However, the filing explicitly states the position is held in the ordinary course and not to influence control, reducing the likelihood of imminent activism. Presence of funds managed by Renaissance entitled to dividends/proceeds clarifies economic exposure across managed accounts.

Corporate Governance Expert

Routine disclosure: clear reporting of ownership and intent, with no controlling stake disclosed.

From a governance perspective, the filing provides transparent attribution of voting and dispositive power to Renaissance, which helps issuers and investors understand who will vote shares. Because the stake is under the 5% threshold, it does not trigger presumptions of influence under common reporting standards. The certification that the position is not held to change control is material to assess potential governance engagement. The filing also clarifies that certain managed funds have economic rights to distributions and sale proceeds.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 1)

COLLEGIUM PHARMACEUTICAL, INC

(Name of Issuer)

Common Stock, par value $0.001 per share

(Title of Class of Securities)

19459J104

(CUSIP Number)

04/01/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 19459J104

1

Names of Reporting Persons

Renaissance Technologies LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 1,521,170.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 1,521,170.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

1,521,170.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

4.82 %

12

Type of Reporting Person (See Instructions)

IA

SCHEDULE 13G

CUSIP No. 19459J104

1

Names of Reporting Persons

Renaissance Technologies Holdings Corporation

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 1,521,170.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 1,521,170.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

1,521,170.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

4.82 %

12

Type of Reporting Person (See Instructions)

HC

SCHEDULE 13G

Item 1.
(a)	Name of issuer: COLLEGIUM PHARMACEUTICAL, INC
(b)	Address of issuer's principal executive offices: 100 TECHNOLOGY CENTER DRIVE, STOUGHTON, MA 02072
Item 2.
(a)	Name of person filing: This Schedule 13G is being filed by Renaissance Technologies LLC ("RTC") and Renaissance Technologies Holdings Corporation ("RTHC").
(b)	Address or principal business office or, if none, residence: 800 Third Avenue New York, New York 10022
(c)	Citizenship: RTC is a Delaware limited liability company, and RTHC is a Delaware corporation.
(d)	Title of class of securities: Common Stock, par value $0.001 per share
(e)	CUSIP No.: 19459J104
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 1521170
(b)	Percent of class: 4.82 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 1521170
	(ii) Shared power to vote or to direct the vote: 0
	(iii) Sole power to dispose or to direct the disposition of: 1521170
	(iv) Shared power to dispose or to direct the disposition of: 0
Item 5.	Ownership of 5 Percent or Less of a Class.
	Ownership of 5 percent or less of a class
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required. Certain funds managed by RTC have the right to receive dividends and proceeds from the sale of the securities which are the subject of this report.
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Renaissance Technologies LLC

Signature:	Brian Felczak
Name/Title:	Chief Financial Officer
Date:	08/13/2025

Renaissance Technologies Holdings Corporation

Signature:	Brian Felczak
Name/Title:	Vice President
Date:	08/13/2025

Exhibit Information

In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, each of the undersigned agrees to the filing on behalf of each of a Statement on Schedule 13G, and all amendments thereto, with respect to the shares of Common Stock, par value $0.001 per share of COLLEGIUM PHARMACEUTICAL, INC.

FAQ

How many Collegium (COLL) shares does Renaissance report owning?

The filers report beneficial ownership of 1,521,170 shares of Collegium common stock.

What percentage of COLL does Renaissance own according to this filing?

The reported stake represents 4.82% of Collegium's common stock class.

Does Renaissance have voting or dispositive power over the reported COLL shares?

Yes. The filing states Renaissance has sole voting power and sole dispositive power over the 1,521,170 shares, and no shared power.

Is the position held to influence control of Collegium (COLL)?

The filers certify the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.

Do any Renaissance-managed funds have economic rights to these COLL shares?

Yes. The filing notes that certain funds managed by Renaissance have the right to receive dividends and proceeds from sale of the securities covered by the report.

Who filed the Schedule 13G/A for COLL?

The Schedule 13G/A was filed by Renaissance Technologies LLC and Renaissance Technologies Holdings Corporation.